Related Experiment Video
Updated: Apr 16, 2026
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Current treatment options for malignant peripheral nerve sheath tumors
1Center for Cancer and Blood Disorders, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC, 20010, USA, dbradfor@childrensnational.org.
Abstract:
Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas characterized by high risk of local recurrence and distant metastasis. The only known curative therapy is complete resection. Adjuvant radiation is recommended for larger lesions or those with more aggressive histology. Given the dismal prognosis in tumors that cannot be cured by surgery alone and the lack of systemic therapy with proven benefit, targeted therapies based on knowledge of activation of the Ras pathway and downstream effectors have been trialed in MPNST, thus far without proven benefit. However, novel or combination therapies based on recent preclinical advances are highly desirable and are the subject of ongoing clinical trials.
Insights
Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas requiring complete resection. Current treatments offer limited benefit for unresectable tumors, driving research into novel targeted therapies.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas with a high propensity for recurrence and metastasis.
- Complete surgical resection is the only curative treatment for MPNST.
- Adjuvant radiation therapy is indicated for larger or histologically aggressive MPNST.
Purpose of the Study:
- To review the current therapeutic landscape for MPNST.
- To highlight the limitations of existing treatments for unresectable MPNST.
- To discuss the potential of novel and combination therapies based on recent advances.
Main Methods:
- Literature review of MPNST treatment modalities.
- Analysis of current clinical trial data for targeted therapies.
- Discussion of preclinical findings and their translation to clinical practice.
Main Results:
- Complete resection remains the cornerstone of curative therapy for MPNST.
- Adjuvant radiation is recommended for specific tumor characteristics.
- Targeted therapies, including Ras pathway inhibitors, have shown limited benefit to date.
- Novel and combination therapies are under investigation.
Conclusions:
- MPNST poses a significant therapeutic challenge due to its aggressive nature and limited systemic treatment options.
- Ongoing clinical trials exploring novel and combination therapies are crucial for improving outcomes.
- Further research into targeted therapies and understanding MPNST biology is warranted.
